文献速递炎症性肠病

随机临床试验:一线英夫利西单抗生物类似药治疗儿童克罗恩病较传统治疗更具成本效益

Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2024-04-21

本研究基于Top-down Infliximab Study in Kids随机对照试验,纳入89例新诊断中重度克罗恩病患儿,比较一线英夫利西单抗生物类似药诱导联合硫唑嘌呤维持与传统诱导治疗的成本效益。结果显示两组2年直接医疗费用相近(€36,784 vs €36,874,p=0.981),但一线英夫利西西单抗组104周临床缓解的比值比为1.56(95%CI 1.03-2.35,p=0.036),为优势策略。

要点

  • 一线英夫利西单抗组104周临床缓解比值比为1.56(95%CI 1.03-2.35,p=0.036)。
  • 两组2年人均直接医疗费用相近:€36,784 vs €36,874(p=0.981)。
  • 一线英夫利西单抗治疗在不增加费用情况下提高缓解几率,为优势策略。

核心结论

  • 一线英夫利西单抗治疗获得更高临床缓解几率且未增加费用,在儿童中重度克罗恩病诊断后前2年为优势策略。

研究设计与样本

  • 基于Top-down Infliximab Study in Kids随机对照试验,纳入新诊断中重度克罗恩病患儿89例(一线英夫利西单抗组44例,传统治疗组45例)。

主要发现

  • 2年人均直接医疗费用:一线英夫利西单抗组€36,784 vs 传统治疗组€36,874(p=0.981)。
  • 104周临床缓解(加权儿童克罗恩病活动指数<12.5)的比值比:一线英夫利西单抗组 vs 传统治疗组为1.56(95%CI 1.03-2.35,p=0.036)。

关键数值与推荐

  • 临床缓解定义为加权儿童克罗恩病活动指数<12.5。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on cost-effectiveness of first-line infliximab in paediatric patients with Crohn's disease are limited. Since biologics are increasingly prescribed and accompanied by high costs, this knowledge gap needs to be addressed. AIM: To investigate the cost-effectiveness of first-line infliximab compared to conventional treatment in children with moderate-to-severe Crohn's disease. METHODS: We included patients from the Top-down Infliximab Study in Kids with Crohn's disease randomised controlled trial. Children with newly diagnosed moderate-to-severe Crohn's disease were treated with azathioprine maintenance and either five induction infliximab (biosimilar) infusions or conventional induction treatment (exclusive enteral nutrition or corticosteroids). Direct healthcare consumption and costs were obtained per patient until week 104. This included data on outpatient hospital visits, hospital admissions, drug costs, endoscopies and surgeries. The primary health outcome was the odds ratio of being in clinical remission (weighted paediatric Crohn's disease activity index<12.5) during 104 weeks. RESULTS: We included 89 patients (44 in the first-line infliximab group and 45 in the conventional treatment group). Mean direct healthcare costs per patient were €36,784 for first-line infliximab treatment and €36,874 for conventional treatment over 2 years (p = 0.981). The odds ratio of first-line infliximab versus conventional treatment to be in clinical remission over 104 weeks was 1.56 (95%CI 1.03-2.35, p = 0.036). CONCLUSIONS: First-line infliximab treatment resulted in higher odds of being in clinical remission without being more expensive, making it the dominant strategy over conventional treatment in the first 2 years after diagnosis in children with moderate-to-severe Crohn's disease. TRIAL REGISTRATION NUMBER: NCT02517684.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Vuijk SA, Jongsma MME, Hoeven BM, et al. Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease. Aliment Pharmacol Ther. 2024. PMID: 38644588. doi:10.1111/apt.18000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。